Axsome Therapeutics
AXSM
355 hedge funds and large institutions have $4.51B invested in Axsome Therapeutics in 2025 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 146 increasing their positions, 104 reducing their positions, and 40 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 104
23% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 40
14% more capital invested
Capital invested by funds: $3.95B → $4.51B (+$563M)
2% more funds holding
Funds holding: 348 → 355 (+7)
7% more call options, than puts
Call options by funds: $87.3M | Put options by funds: $81.5M
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
2.36% less ownership
Funds ownership: 76.88% → 74.53% (-2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$68.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$47.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$47.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$36.2M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$33.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$136M |
| 2 |
RI
RTW Investments
New York
|
-$44.8M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$44.2M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$43.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37.4M |
AXSM Hedge Fund Activity: Q3 2025 in Review
355 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2025, worth a combined $4.51B — up 14% from $3.95B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new AXSM positions and 40 closed out — a net gain of 9 holders — while 146 added to existing stakes and 104 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $68.7M. The largest seller was BVF Inc, cutting an estimated $136M.
- 355 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2025, up from 348 in Q2 2025.
- Funds reported $4.51B of Axsome Therapeutics stock for Q3 2025, up 14% quarter-over-quarter.
- 49 funds opened new Axsome Therapeutics positions in Q3 2025 and 40 closed out, a net change of +9 holders.
- The largest Axsome Therapeutics buyer in Q3 2025 was Wellington Management Group, an estimated $68.7M added.
- The largest Axsome Therapeutics seller in Q3 2025 was BVF Inc, an estimated $136M sold.
Based on aggregated 13F filings for Q3 2025.